Vasgene (Los Angeles, CA, USA) and CNIO Biotechnology (Madrid, Spain) have both explored EphB4 and ephrinB2 as promising targets because of their crucial involvement in the formation of tumour vasculature. This evidence concerns the gene EFNB2 and neoplasm.